COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,557 Articles (22,400 medRxiv, 8,157 bioRxiv)

Most recent first Previous |  Page 652: Articles 6511-6520  | Next

Differential COVID-19 infection rates in children, adults, and elderly: evidence from 38 pre-vaccination national seroprevalence studies
Axfors, C., Pezzullo, A. M., Contopoulos-Ioannidis, D., Apostolatos, A., Ioannidis, J. P. A.
10.1101/2022.06.28.22277034 — Posted: 2022-06-29
Masks Do No More Than Prevent Transmission:Theory and Data Undermine the Variolation Hypothesis
Koelle, K., Lin, J., Zhu, H., Antia, R., Lowen, A., Weissman, D.
10.1101/2022.06.28.22277028 — Posted: 2022-06-29
Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022
Stoliaroff, A., Peine, C., Herath, T., Lachmann, J., Doerre, A., Perriat, D., Nitsche, A., Michel, J., Rinner, T., Stern, D., Treindl, F., Hofmann, N., Grossegesse, M., Kohl, C., Brinkmann, A., Meyer, T., Dorner, B., Hein, S., Werel, L., Hildt, E., Glaeser, S., Schuehlen, H., Isner, C., Peric, A., Ghouzi, A., Reichardt, A., Janneck, M., Lock, G., Schaade, L., Wichmann, O., Harder, T.
10.1101/2022.06.28.22276303 — Posted: 2022-06-29
Understanding reported COVID-19 cases in England following changes to testing, between November 2021 and April 2022
Halford, F., Nash, S. G., Tessier, E., Kall, M., Dabrera, G.
10.1101/2022.06.28.22276549 — Posted: 2022-06-29
Retrospective analysis of SARS-CoV-2 omicron invasion over delta in French regions in 2021-22: a status-based multi-variant model
Haschka, T., Vergu, E., Roche, B., Poletto, C., Opatowski, L.
10.1101/2022.06.28.22277015 — Posted: 2022-06-29
Protection from Omicron infection in residents of nursing and retirement homes in Ontario, Canada
Breznik, J. A., Rahim, A., Kajaks, T., Hagerman, M., Bilaver, L., Colwill, K., Dayam, R., Gingras, A.-C., Verschoor, C. P., McElhaney, J. E., Bramson, J. L., Bowdish, D. M. E., Costa, A. P.
10.1101/2022.06.28.22277016 — Posted: 2022-06-29
Insights into the microevolution of SARS-ACE2 Interactions: In-silico analysis of glycosylation and SNP pattern
Pavan Kumar, M., Maity, A., Ghosh, S. K., Chandran, T.
10.1101/2022.06.29.498095 — Posted: 2022-06-29
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
Hu, Y., Lewandowski, E. M., Tan, H., Morgan, R. T., Zhang, X., Jacobs, L. M., Butler, S. G., Mongora, M. V., Choy, J. S., Chen, Y., Wang, J.
10.1101/2022.06.28.497978 — Posted: 2022-06-28
Peptide from NSP7 is able to form amyloid-like fibrils: artifact or challenge to drug design?
Garmay, Y. P., Rubel, A. A., Egorov, V. V.
10.1101/2022.06.28.497929 — Posted: 2022-06-28
Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
Fan, C., Cohen, A. A., Park, M., Hung, A. F.-H., Keeffe, J. R., Gnanapragasam, P. N., Lee, Y. E., Kakutani, L. M., Wu, Z., Malecek, K. E., Williams, J. C., Bjorkman, P. J.
10.1101/2022.06.28.497989 — Posted: 2022-06-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).